SWard, Author at Break Through Cancer

November 20, 2025November 20, 2025

Conquering Cancer: Innovations Closing Gaps and Improving Outcomes | Milken Institute

Jesse Boehm at the Future of Health Summit 2025: Conquering Cancer Panel We are pleased to share that our Chief Scientific Officer, Jesse Boehm, participated as a speaker at the 2025 Future of Health Summit, hosted by the Milken Institute in Washington, DC. The Summit brought together more than 200 experts and 1,400 participants to discuss biomedical innovation, equitable access, chronic disease prevention, and the future of global health. As part of the program, Jesse joined the panel “Conquering Cancer: Innovations, Closing Gaps and Improving Outcomes,” contributing perspectives on the power of radical collaboration and team-science models to accelerate progress......

November 19, 2025November 21, 2025

Canadian scientists join international osteosarcoma team to solve aggressive cancer that targets children and young adults | Globe and Mail

Canadian scientists join international osteosarcoma team to solve aggressive cancer that targets children and young adults November 14, 2025 More than 45 years after Terry Fox ran his Marathon of Hope, a new generation of scientists—backed by a coalition of donors and home-grown Canadian ingenuity—unites to defeat osteosarcoma, the cancer that took Terry's life. Read More at Globe and Mail....

November 18, 2025November 21, 2025

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say | American College of Surgeons

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say November 17, 2025 Expanding access to fallopian tube removal during planned abdominal surgeries in post-reproductive women could save thousands of lives every year. Read More at American College of Surgeons...

October 10, 2025October 14, 2025

Real-Time Biopsies Reveal Hidden Insights into Glioblastoma Therapy Response | Bioengineer.org

Real-Time Biopsies Reveal Hidden Insights into Glioblastoma Therapy Response October 08, 2025 In a groundbreaking advancement for glioblastoma research, scientists from Break Through Cancer’s Accelerating Glioblastoma Therapies Through Serial Biopsies TeamLab have demonstrated that the oncolytic virus therapy, CAN-3110, sparks a profound and previously undetectable immune response deep within recurrent glioblastoma tumors. Read More at Bioengineer.org...

October 10, 2025

Experimental Glioblastoma Trial Findings Could Lead to Change in Patient Monitoring and Therapy | GEN

Experimental Glioblastoma Trial Findings Could Lead to Change in Patient Monitoring and Therapy October 08, 2025 Researchers headed by teams at Mass General Brigham Cancer Institute and Harvard Medical School have acquired serial biopsies from two recurrent glioblastoma (rGBM) patients who were involved in an immunotherapy clinical trial, allowing the scientists to safely monitor brain tumor progression and the patients’ responses to treatment. The researchers say their approach captured details that are indiscernible by even the most advanced of imaging methods. Read More at Genetic Engineering and Biotechnology News...

October 10, 2025October 10, 2025

Serial Biopsies Reveal Immune Activation During Treatment for Recurrent Glioblastoma | Gene Online

Serial Biopsies Reveal Immune Activation During Treatment for Recurrent Glioblastoma October 08, 2025 by Mark Chiang A recent multi-institutional study has demonstrated that repeated sampling of brain tumor tissue can reveal immune system activation in response to cancer treatment for patients with recurrent glioblastoma (GBM). The research, conducted by the Accelerating GBM Therapies Through Serial Biopsies TeamLab and led by investigators from the Mass General Brigham Cancer Institute, highlights the potential of serial biopsies to detect treatment responses that may not be visible through traditional imaging techniques. Read More at Gene Online...

October 8, 2025October 8, 2025

Real-Time Biopsies Uncover Hidden Response to Glioblastoma Therapy

Real-Time Biopsies Uncover Hidden Response to Glioblastoma Therapy Early clinical trial results show that serial brain biopsies reveal immune activity in brain cancer not captured by standard scans News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) October 08, 2025 – A new study led by Break Through Cancer’s Accelerating Glioblastoma (GBM) Therapies Through Serial Biopsies TeamLab has revealed that an engineered virus therapy, CAN-3110, triggered powerful immune responses deep inside glioblastoma tumors that were invisible to standard imaging like MRI, according to early analyses of two patients with recurrent GBM. Published today in Science Translational Medicine,......

October 1, 2025March 17, 2026

𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋 launches a $15M multi-institute pediatric osteosarcoma research initiative | The Cancer Letter

Break Through Cancer launches a $15M multi-institute pediatric osteosarcoma research initiative September 26, 2025 Vol.51 No.35 Break Through Cancer has launched the Defying Osteosarcoma TeamLab, an initiative that brings together more than 20 researchers from eight institutions in a coordinated, multi-year effort focused on improving pediatric osteosarcoma care. Read More at The Cancer Letter...

October 1, 2025October 3, 2025

Can a virtual team of researchers break a 40-year logjam in this rare cancer? | Endpoints News

Can a virtual team of researchers break a 40-year logjam in this rare cancer? John Carroll August 25, 2025 When Mac Tichenor’s son Willie died of osteosarcoma at the age of 19 back in 2006, oncologists still relied on a decades-old chemo regimen called MAP — high-dose methotrexate, combined with doxorubicin and cisplatin. Typically, for young patients with the rare bone cancer, it staved off death for a while. Read More at Endpoints News...

October 1, 2025October 3, 2025

Detecting minimal residual disease may be key to preventing ovarian cancer recurrence | Healio

Detecting minimal residual disease may be key to preventing ovarian cancer recurrence By Josh Friedman Fact checked by Heather Biele August 27, 2025 Key takeaways: Women who had minimal residual disease following first-line ovarian cancer treatment had significantly worse OS. Many women who appeared in remission had surgically- or ctDNA-detected minimal residual disease. Read More at Healio...